Literature DB >> 8356847

Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.

M Roberts1, I Cropley, S Chatfield, G Dougan.   

Abstract

Intranasal immunization of adult female Balb/c mice with the Bordetella pertussis antigens FHA or P.69, greatly enhanced their ability to clear B. pertussis from their lungs following aerosol challenge compared with ovalbumin-immunized controls. Low numbers of lymphocytes secreting antibodies (IgG, IgA and IgM) against the immunizing antigens could be isolated from the lungs of immunized mice. Following aerosol challenge with B. pertussis there was a large increase in the numbers of FHA or P.69-specific antibody-secreting cells in the lungs of mice immunized with these antigens. Intranasal immunization, particularly with FHA, also primed mice to develop a systemic serum anti-pertussis antibody response subsequent to challenge. However, pulmonary clearance of B. pertussis correlated most closely with the local antibody response. A strong anti-FHA response was demonstrated in the lungs of mice that received a booster dose of FHA 9 months after their previous exposure to FHA, demonstrating that long immunological memory can develop in the murine respiratory tract following direct application of pertussis antigens to the respiratory tract mucosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8356847     DOI: 10.1016/0264-410x(93)90363-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens.

Authors:  A Bacon; J Makin; P J Sizer; I Jabbal-Gill; M Hinchcliffe; L Illum; S Chatfield; M Roberts
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization.

Authors:  P A Cotter; M H Yuk; S Mattoo; B J Akerley; J Boschwitz; D A Relman; J F Miller
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

3.  Seroprevalence of pertussis in China: need to improve vaccination strategies.

Authors:  Yinghua Xu; Lichan Wang; Jin Xu; Xinjian Wang; Chen Wei; Peng Luo; Xiao Ma; Qiming Hou; Junzhi Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-09       Impact factor: 3.452

Review 4.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Bordetella filamentous hemagglutinin plays a critical role in immunomodulation, suggesting a mechanism for host specificity.

Authors:  Carol S Inatsuka; Steven M Julio; Peggy A Cotter
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

6.  Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.

Authors:  B M van den Berg; H Beekhuizen; F R Mooi; R van Furth
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

7.  Probing the function of Bordetella bronchiseptica adenylate cyclase toxin by manipulating host immunity.

Authors:  E T Harvill; P A Cotter; M H Yuk; J F Miller
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection.

Authors:  Steven M Julio; Carol S Inatsuka; Joseph Mazar; Christine Dieterich; David A Relman; Peggy A Cotter
Journal:  Mol Microbiol       Date:  2009-02-10       Impact factor: 3.501

9.  Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection.

Authors:  D H Jones; B W McBride; C Thornton; D T O'Hagan; A Robinson; G H Farrar
Journal:  Infect Immun       Date:  1996-02       Impact factor: 3.441

10.  Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization.

Authors:  R A Daynes; E Y Enioutina; S Butler; H H Mu; Z A McGee; A Araneo B
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.